Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 5/20 | 0.42 |
| ▸ | MYC | P01106 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.38 |
| ▸ | METAP2 | P50579 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | AHR | P35869 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3628103 | 0.88 | KDM4E (0.46) | PARP1ALDH1A1HPGDL3MBTL1KDM4E | |
| SCHEMBL1267037 | 0.83 | PARP1 (0.43) | PARP1MYCALDH1A1HPGDL3MBTL1 | |
| SCHEMBL31678934 | 0.83 | PARP1 (0.43) | PARP1MYCALDH1A1HPGDL3MBTL1 | |
| SCHEMBL11930069 | 0.82 | ALDH1A1 (0.57) | MYCALDH1A1HPGDLMNAHTT | |
| SCHEMBL22024137 | 0.82 | PARP1 (0.39) | PARP1MYCALDH1A1HPGDL3MBTL1 | |
| SCHEMBL20421489 | 0.82 | PARP1 (0.38) | PARP1MYCALDH1A1HPGDL3MBTL1 | |
| SCHEMBL22129807 | 0.81 | KDM4E (0.39) | MYCALDH1A1HPGDKDM4EHSD17B10 | |
| SCHEMBL5506244 | 0.81 | MMP2 (0.41) | PARP1ALDH1A1HPGDL3MBTL1KDM4E | |
| SCHEMBL28819980 | 0.81 | CA2 (0.43) | PARP1ALDH1A1HPGDL3MBTL1KDM4E | |
| SCHEMBL9509593 | 0.80 | CA1 (0.49) | MYCALDH1A1HPGDHTTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11802125-B2 | Functionalized heterocyclic compounds as antiviral agents | ENANTA PHARMACEUTICALS, INC. | 2023-10-31 | — | — | US | disclosed |
| US-11802125-B2 | Functionalized heterocyclic compounds as antiviral agents | ENANTA PHARMACEUTICALS, INC. | 2023-10-31 | — | — | US | disclosed |
| US-11198693-B2 | Functionalized heterocycles as antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2021-12-14 | — | — | US | disclosed |
| US-20210292320-A1 | FUNCTIONALIZED HETEROCYCLIC COMPOUNDS AS ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2021-09-23 | — | — | US | disclosed |
| US-20200165249-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2020-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210292320-A1 | FUNCTIONALIZED HETEROCYCLIC COMPOUNDS AS ANTIVIRAL AGENTS | HAVCR2, HDGF, HCCS | PARP1 1707/4885MYC 595/4885ALDH1A1 2297/4885 |
| US-11802125-B2 | Functionalized heterocyclic compounds as antiviral agents | HAVCR2, HDGF, HCCS | PARP1 1707/4885MYC 595/4885ALDH1A1 2297/4885 |
| US-11198693-B2 | Functionalized heterocycles as antiviral agents | HCCS, HAVCR2, HDGF | PARP1 2120/4885MYC 553/4885ALDH1A1 2352/4885 |
| US-20200165249-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | HCCS, HAVCR2, HDGF | PARP1 2120/4885MYC 553/4885ALDH1A1 2352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.